🔴 Citius Pharmaceuticals is trading 11.33% down in pre-market after revenue shortfall and limited cash runway

Citius Pharmaceuticals is trading 11.33% down now at $0.67 after its August 14, 2026 fiscal third-quarter report highlighted a revenue shortfall and limited cash runway.

• Quarterly revenue was $1.49 million; reported cash was $17 million, and management projected liquidity only through November 2026.
• LYMPHIR adoption improved, including a 31% increase in institutional vial orders, but rising losses, commercial-launch expenses, and revenue below analyst expectations weighed on the shares.
• The broader market was mixed-to-positive, making company-specific earnings concerns the primary catalyst.